Section of Neuroinfectious Disease

Chief

Faculty

Research

Recent publications

• Behavioral and psychological symptoms of dementia and Alzheimer’s disease progression in Down syndrome
  December 1, 2025
  Behavioral and psychological symptoms of dementia and Alzheimer’s disease progression in Down syndromethe Alzheimer Biomarker Consortium – Down syndrome, Dec 2025, In: Journal of neurodevelopmental disorders. 17, 1, 19.Research output: Contribution to journal › Article › peer-review
• Exploring the Remote Administration of a Performance-Based Functional Assessment
  June 1, 2025
  Exploring the Remote Administration of a Performance-Based Functional AssessmentKeleman, A. A., Bollinger, R. M., Rodakowski, J., Chang, C. H., Kehrer-Dunlap, A. L., Ances, B. M. & Stark, S. L., Jun 2025, In: Journal of Applied Gerontology. 44, 6, p. 981-993 13 p.Research output: Contribution to journal › Article › peer-review
• The striatum is an early, accurate indicator of amyloid burden using [¹¹C]PiB in Down syndrome: Comparison of two radiotracers
  April 1, 2025
  The striatum is an early, accurate indicator of amyloid burden using [11C]PiB in Down syndrome: Comparison of two radiotracersMcLachlan, M., Bettcher, B., McVea, A., DiFilippo, A., Zammit, M., LeMerise, L., Rouanet, J., Price, J., Tudorascu, D., Laymon, C., Keator, D., Lao, P., Brickman, A. M., Fryer, T., Hartley, S., Ances, B. M., Rosas, H. D., Johnson, S., Betthauser, T. & Stone, C. K. & 6 others, Zaman, S., Handen, B., Head, E., Mapstone, M., Christian, B. T. & Investigators, A. B. C. D. S., Apr 2025, In: Alzheimer's and Dementia. 21, 4, e70141.Research output: Contribution to journal › Article › […]
• Complementary value of molecular, phenotypic, and functional aging biomarkers in dementia prediction
  April 1, 2025
  Complementary value of molecular, phenotypic, and functional aging biomarkers in dementia predictionAlzheimer’s Disease Neuroimaging Initiative Consortium, Apr 2025, In: GeroScience. 47, 2, p. 2099-2118 20 p.Research output: Contribution to journal › Article › peer-review
• Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial
  April 1, 2025
  Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialDominantly Inherited Alzheimer's Disease–Trials Unit, Apr 2025, In: The Lancet Neurology. 24, 4, p. 316-330 15 p.Research output: Contribution to journal › Article › peer-review